Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-AGT01 RVR · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| ALN-AGT1 RVR | EXPERIMENTAL | Participants will be administered a single dose of zilebesiran followed by a single dose of ALN-AGT01 RVR. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of zilebesiran followed by a single dose of placebo. |
| ALN-AGT01 RVR | EXPERIMENTAL | Participants will be administered a single dose of ALN-AGT01 RVR. |
| Name | Type | Description |
|---|---|---|
| ALN-AGT01 RVR | DRUG | ALN-AGT01 RVR will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
| Zilebesiran | DRUG | Zilebesiran will be administered SC |
Part A: Inclusion Criteria * Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg * Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications Part B: Inclusion Criteria...
ALN-AGT01 RVR is an investigational drug being studied for use in healthy volunteers and in adult patients with mild to moderate hypertension who have been pretreated with zilebesiran. It is currently in clinical development and is not approved by the FDA.
ALN-AGT01 RVR is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol ALNY.
ALN-AGT01 RVR is in Phase 1 clinical development. One Phase 1 trial in healthy volunteers has been completed, and a Phase 2 trial in patients with hypertension is currently recruiting participants.
ALN-AGT01 RVR has been studied in two clinical trials. NCT06675565 is a completed Phase 1 study in healthy volunteers in Canada. NCT07553442 is a recruiting Phase 2 study in patients with mild to moderate hypertension in the United States.
No, ALN-AGT01 RVR is not the same as zilebesiran. It is being studied in patients who have been pretreated with zilebesiran, indicating that the two drugs are distinct and used in sequence in the clinical trial setting.